Below are the most recent publications written about "Biomarkers, Tumor" by people in Profiles.
-
Alam R, Reva A, Edwards DG, Lege BM, Munoz-Arcos LS, Reduzzi C, Singh S, Hao X, Wu YH, Tian Z, Natalee LM, Damle G, Demircioglu D, Wang Y, Wu L, Molteni E, Hasson D, Lim B, Gugala Z, Chipuk JE, Lang JE, Sparano JA, Cheng C, Cristofanilli M, Xiao H, Zhang XH, Bado IL. Bone-Induced HER2 Promotes Secondary Metastasis in HR+/HER2- Breast Cancer. Cancer Discov. 2025 Apr 02; 15(4):818-837.
-
Lucas CG, Gross AM, Romo CG, Dehner CA, Lazar AJ, Miettinen M, Pekmezci M, Quezado M, Rodriguez FJ, Stemmer-Rachamimov A, Viskochil D, Perry A. Consensus recommendations for an integrated diagnostic approach to peripheral nerve sheath tumors arising in the setting of Neurofibromatosis Type 1. Neuro Oncol. 2025 Mar 07; 27(3):616-624.
-
Yarman Y, Post R, Breslin Z, Solomides CC, Gargano SM. Utility of Proliferation Markers Ki-67 and PHH3 in Predicting Malignancy in Basaloid Salivary Gland Neoplasms: A Study Using Digital Image Analysis of Cytology Cell Blocks. Diagn Cytopathol. 2025 May; 53(5):238-245.
-
Wei S, Patchefsky AS, Pei J, Brown SA, Basu Mallick A, Wang Z, Jiang W. PHF1::TFE3-positive fibromyxoid sarcoma? Report of 2 cases and review of 13 cases of PHF1::TFE3-positive ossifying fibromyxoid tumor in the literature. Am J Clin Pathol. 2025 02 12; 163(2):224-230.
-
Mastrolonardo EV, Nunes KL, Llerena P, Nikitina A, Sobol A, Scott ER, Tuluc M, Davitt CJH, Scher J, Tekumalla S, Mann D, Henao C, Jegede V, Gargano S, Harshyne LA, Alnemri A, Tyshevich A, Kushnarev V, Chasse M, Sookiasian D, Axelrod R, Zhan T, Leiby BE, Old M, Seim N, Mahoney MG, Martinez-Outschoorn U, Cognetti DM, Curry JM, Prendergast GC, Argiris A, South AP, Linnenbach AJ, Johnson JM, Luginbuhl AJ. Response-Adaptive Surgical Timing in Neoadjuvant Immunotherapy Demonstrates Enhanced Pathologic Treatment Response in Head and Neck Squamous Cell Carcinoma. Clin Cancer Res. 2025 02 03; 31(3):515-528.
-
Lasota J, Kaczorowski M, Chlopek M, Milek-Krupa J, Szczepaniak M, Ylaya K, Chodyna M, Izycka-Swieszewska E, Scherping A, Czapiewski P, Dziuba I, Kato Y, Halon A, Kowalik A, Miettinen M. An immunohistochemical and molecular genetic study of 60 colorectal carcinoma brain metastases in pursuit of predictive biomarkers for cancer therapy. Hum Pathol. 2025 Jan; 155:105717.
-
Hrizat AS, Doxzon KA, O'Neill R, Post RP, Brachtel EF. Evaluation of HER2-Low breast carcinoma in metastatic settings: a cytological approach to proliferation and survival. J Am Soc Cytopathol. 2025 May-Jun; 14(3):182-190.
-
Mittal P, Battaglin F, Baca Y, Xiu J, Farrell A, Soni S, Lo JH, Torres-Gonzalez L, Algaze S, Jayachandran P, Ashouri K, Wong A, Zhang W, Yu J, Zhang L, Weinberg BA, Lou E, Shields AF, Goldberg RM, Marshall JL, Goel S, Singh IK, Lenz HJ. Comprehensive characterization of MCL-1 in patients with colorectal cancer: Expression, molecular profiles, and outcomes. Int J Cancer. 2025 04 15; 156(8):1583-1593.
-
Hrizat AS, Lin R, Eberle-Singh J, O'Neill R, Xia Y, Testa JR, Uzzo R, McCue PA, Yang H, Li L. Tumor infiltrating T-cells and loss of expression of SWI/SNF genes in varying stages of clear cell renal cell carcinoma. Pathol Res Pract. 2025 Feb; 266:155774.
-
Warmke LM, Ameline B, Fritchie KJ, Dehner CA, Agaimy A, Din NU, Miettinen MM, Dermawan JK, Gross JM, Thangaiah JJ, Chrisinger JSA, Suster DI, Perret R, Le Loarer F, Charville GW, Buehler D, Yeung MCF, Smith BF, Baumhoer D, Davis JL. YAP1::KMT2A-rearranged sarcomas harbor a unique methylation profile and are distinct from sclerosing epithelioid fibrosarcoma and low-grade fibromyxoid sarcoma. Virchows Arch. 2025 Mar; 486(3):457-477.